No profile data available.
Simulations Plus, Inc. (SLP) is a healthcare company in the medical sector application systems industry, based in Research Triangle Park, United States, with about 212 full-time employees.
It reported revenue of $79.18 million for fiscal year 2025, up 13.1% from fiscal year 2024, and net income of -$64.72 million. In Q3 2026 (the quarter ended May 31, 2026) revenue was $21.89 million, up 7.5% from a year before. Its largest business segment, Software, brought in 58% of segment revenue in fiscal year 2025; Americas was the largest region with 73%. Its market capitalization was $374.16 million as of October 5, 2026.
Figures from company filings and market data; latest fiscal year ended August 31, 2025; market data as of October 5, 2026.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments.
Simulations Plus reported $79.18 million in revenue for fiscal year 2025, up 13.1% from $70.01 million in fiscal year 2024. In Q3 2026 revenue was $21.89 million.
Software, with $45.83 million or 58% of segment revenue in fiscal year 2025. Next: Services (42%).
Americas: 73% of revenue by region in fiscal year 2025, followed by EMEA (18%).
$374.16 million as of October 5, 2026.
Listed companies of a similar size in the same industry (medical sector application systems) include Phreesia, Inc. (PHR), SOPHiA Genetics SA (SOPH), Claritev Corp (CTEV), Definitive Healthcare Corp. (DH).